What Happened?
Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ: HALO) jumped 5.2% in the afternoon session after an analyst reiterated a Buy rating on the stock, and a partner company, argenx, presented positive new data for a drug that utilizes Halozyme's technology.
Benchmark maintained its Buy rating and $90 price target on Halozyme, with the firm noting the stock has potential for gains this year.
The positive sentiment was reinforced by news from partner company argenx, which announced it would present new data for its drug, Efgartigimod. This development is significant for Halozyme because Efgartigimod uses its ENHANZE® drug delivery technology. This technology helps deliver biologic drugs through a subcutaneous injection, which is an injection under the skin. Positive results for a partner's product using ENHANZE can be viewed as a validation of Halozyme's core technology.
Is now the time to buy Halozyme Therapeutics? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Halozyme Therapeutics’s shares are not very volatile and have only had 3 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The previous big move we wrote about was 21 days ago when the stock dropped 2.9% on the news that the April PPI report showed wholesale inflation accelerating to 6% annually, with service-sector prices rising at their fastest pace in four years.
Healthcare companies, drug makers, hospitals, and insurers, earn revenue from clinical services and product sales. While the sector is traditionally defensive, the hot PPI print creates a two-pronged headwind. First, rising service-sector inflation (up 1.2% monthly) increases the operating costs for hospital systems and providers. Second, as inflation becomes a dominant political issue, drug companies' visible price-setting power makes them a primary target for regulatory intervention.
Halozyme Therapeutics is flat since the beginning of the year, and at $69.84 per share, it is trading 14% below its 52-week high of $81.23 from February 2026. Investors who bought $1,000 worth of Halozyme Therapeutics’s shares 5 years ago would now be looking at an investment worth $1,798.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
